drugset
drugset / Trial / NCT05891548

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

NCT05891548 ↗

Phase 2 Completed 60 enrolled Clearside Biomedical, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.

Timeline

Start
2023-05-31
Primary completion
2024-08-20
Completion
2024-08-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic 2 mg Intravitreal
Subject CLS-AX Small molecule 1 mg Other

Indications

age-related macular degeneration